Literature DB >> 29112446

Relevance of Half-Life in Drug Design.

Dennis A Smith, Kevin Beaumont1, Tristan S Maurer1, Li Di2.   

Abstract

Drug half-life has important implications for dosing regimen and peak-to-trough ratio at the steady state. A half-life of 12-48 h is generally ideal for once daily dosing of oral drugs. If the half-life is too short, it may require more frequent dosing in order to maintain desired exposures and avoid unnecessarily high peak concentrations. This may pose challenges to achieving optimal efficacy, safety, and patient compliance. If the half-life is too long, the time over which accumulation and subsequent elimination occur may be prolonged. This may pose problems with managing adverse effects and the design of efficient clinical trials. Half-life is a key parameter for optimization in research and development. Structural modification to affect clearance, and to a lesser extent volume of distribution, is the preferred means of modulating half-life. An effective approach to half-life optimization requires an understanding of the many pitfalls associated with its estimation and interpretation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29112446     DOI: 10.1021/acs.jmedchem.7b00969

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  20 in total

1.  Late-Stage Functionalization of Platensimycin Leading to Multiple Analogues with Improved Antibacterial Activity in Vitro and in Vivo.

Authors:  Youchao Deng; Xiang Weng; Yuling Li; Meng Su; Zhongqing Wen; Xinxin Ji; Nan Ren; Ben Shen; Yanwen Duan; Yong Huang
Journal:  J Med Chem       Date:  2019-07-02       Impact factor: 7.446

2.  Strategy for Extending Half-life in Drug Design and Its Significance.

Authors:  Hakan Gunaydin; Michael D Altman; J Michael Ellis; Peter Fuller; Scott A Johnson; Brian Lahue; Blair Lapointe
Journal:  ACS Med Chem Lett       Date:  2018-04-02       Impact factor: 4.345

3.  In Vitro - in Vivo Extrapolation of Hepatic Clearance in Preclinical Species.

Authors:  David A Tess; Sangwoo Ryu; Li Di
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.200

4.  Structure-Activity relationship of 1-(Furan-2ylmethyl)Pyrrolidine-Based Stimulation-2 (ST2) inhibitors for treating graft versus host disease.

Authors:  Xinrui Yuan; Hua Jiang; Denggang Fu; Aaron Robida; Krishani Rajanayake; Hebao Yuan; Bo Wen; Duxin Sun; Brennan T Watch; Krishnapriya Chinnaswamy; Jeanne A Stuckey; Sophie Paczesny; Jason C Rech; Chao-Yie Yang
Journal:  Bioorg Med Chem       Date:  2022-07-22       Impact factor: 3.461

5.  Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.

Authors:  Frederick W Goldberg; Attilla K T Ting; David Beattie; Gillian M Lamont; Charlene Fallan; M Raymond V Finlay; Beth Williamson; Marianne Schimpl; Alexander R Harmer; Oladipupo B Adeyemi; Pär Nordell; Anna S Cronin; Mercedes Vazquez-Chantada; Derek Barratt; Antonio Ramos-Montoya; Elaine B Cadogan; Barry R Davies
Journal:  ACS Med Chem Lett       Date:  2022-07-07       Impact factor: 4.632

6.  Utilization of Metabolite Identification and Structural Data to Guide Design of Low-Dose IDO1 Inhibitors.

Authors:  Brett Hopkins; Hongjun Zhang; Indu Bharathan; Derun Li; Qinglin Pu; Hua Zhou; Theodore A Martinot; Xavier Fradera; Alfred Lammens; Charles A Lesburg; Ryan D Cohen; Jeanine Ballard; Ian Knemeyer; Karin Otte; Stella Vincent; J Richard Miller; Nicolas Solban; Mangeng Cheng; Prasanthi Geda; Nadya Smotrov; Xuelei Song; David Jonathan Bennett; Yongxin Han
Journal:  ACS Med Chem Lett       Date:  2021-08-18       Impact factor: 4.632

7.  How effective are ionization state-based QSPKR models at predicting pharmacokinetic parameters in humans?

Authors:  Anish Gomatam; Blessy Joseph; Poonam Advani; Mushtaque Shaikh; Krishna Iyer; Evans Coutinho
Journal:  Mol Divers       Date:  2022-10-11       Impact factor: 3.364

8.  LipMetE (Lipophilic Metabolism Efficiency) as a Simple Guide for Half-Life and Dosing Regimen Prediction of Oral Drugs.

Authors:  Giuseppe Cecere; Laura Guasch; Andres M Olivares-Morales; Kenichi Umehara; Antonia F Stepan
Journal:  ACS Med Chem Lett       Date:  2022-08-23       Impact factor: 4.632

9.  Will Cannabis or Cannabinoids Protect You from SARS-CoV-2 Infection or Treat COVID-19?

Authors:  Joshua D Brown; Amie J Goodin
Journal:  Med Cannabis Cannabinoids       Date:  2022-02-25

Review 10.  Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.

Authors:  Denise A Cobb; Nathan A Smith; Benson J Edagwa; JoEllyn M McMillan
Journal:  Expert Opin Drug Deliv       Date:  2020-07-06       Impact factor: 6.648

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.